Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer

Trial Profile

Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2011

At a glance

  • Drugs Capecitabine; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top